10-Q: OneMedNet Corporation Reports Mixed Results in Q2 2024 Amidst Strategic Shift and Financial Restructuring

OneMedNet Corporation's Q2 2024 results show a revenue increase driven by web imaging, offset by a decrease in subscription revenue, alongside significant changes in financial structure and management.

Summary

• OneMedNet Corporation's Q2 2024 results show a 31% increase in total revenue compared to Q2 2023, reaching $227 thousand, driven by a significant increase in web imaging revenue to $86 thousand, while subscription revenue decreased by 18% to $141 thousand.
• The company's cost of revenue increased by 43% to $329 thousand, resulting in a gross margin loss of $102 thousand.
• Operating expenses increased by 55% to $2.352 million, with general and administrative expenses rising significantly by 175% to $1.716 million, while research and development expenses decreased by 34% to $383 thousand.
• The company reported a net loss of $3.589 million for the quarter, compared to a net loss of $9.601 million in the same period last year.
• For the six months ended June 30, 2024, total revenue increased by 34% to $476 thousand, with web imaging revenue increasing by 738% to $134 thousand, while subscription revenue increased by 1% to $342 thousand.
• The company's cost of revenue for the six months ended June 30, 2024, was $646 thousand, resulting in a gross margin loss of $170 thousand.
• Operating expenses for the six months ended June 30, 2024, increased by 51% to $4.384 million, with general and administrative expenses rising by 164% to $3.073 million.
• The company reported a net loss of $5.698 million for the six months ended June 30, 2024, compared to a net loss of $17.444 million in the same period last year.
• The company has an accumulated deficit of $97.1 million as of June 30, 2024, and its unrestricted cash balance of $0.4 million is not adequate to fund its operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with some positive revenue growth but significant concerns about profitability, cash flow, and internal controls. The going concern uncertainty and the need for additional financing are major red flags, leading to a low sentiment score.

Positives

• Total revenue increased by 31% in Q2 2024 compared to Q2 2023, driven by a significant increase in web imaging revenue.
• The company's net loss decreased to $3.589 million in Q2 2024 from $9.601 million in Q2 2023.
• Web imaging revenue increased significantly, indicating a successful shift in focus.
• The company secured a $1.5 million convertible promissory note through a SEPA with Yorkville, providing additional funding.

Negatives

• Subscription revenue decreased by 18% in Q2 2024, indicating a decline in the BEAM platform.
• The company's cost of revenue increased by 43% in Q2 2024, impacting gross margin.
• General and administrative expenses increased significantly by 175% in Q2 2024, primarily due to increased professional fees as a public company.
• The company's accumulated deficit reached $97.1 million as of June 30, 2024.
• The company's unrestricted cash balance of $0.4 million is not adequate to fund its operations for the next twelve months, raising substantial doubt about its ability to continue as a going concern.
• The company has material weaknesses in its internal controls over financial reporting.

Risks

• The company's ability to continue as a going concern is uncertain due to its low cash balance and recurring losses.
• The company may not be able to secure additional financing in a timely manner or on favorable terms.
• The company's internal controls over financial reporting are not effective due to material weaknesses.
• The company is subject to risks common to companies in the markets it serves, including global economic conditions, customer demand fluctuations, and competition.
• The company is reliant on third-party suppliers.
• The company faces the risk of intellectual property infringement claims.
• The company's ability to expand its organization and retain key personnel is uncertain.
• The company is subject to potential costs resulting from lawsuits.

Future Outlook

The company plans to raise additional working capital through equity or debt offerings and hopes to attain profitable operations to fulfill its operating and capital requirements for at least 12 months from the date of the issuance of the condensed consolidated financial statements. The company is also shifting its focus from the BEAM platform to iRWD sales.

Management Comments

• Management plans to raise additional working capital through an equity or debt offering.
• Management hopes to attain profitable operations to fulfill its operating and capital requirements.
• Management intends to raise cash for operations through debt and equity offerings.

Industry Context

The company operates in the healthcare software industry, which is characterized by rapid technological advancements and intense competition. The shift towards digital medical image management and data analytics is a growing trend, and OneMedNet is positioning itself to capitalize on this trend with its iRWD platform. However, the company faces competition from established players and new entrants in the market.

Comparison to Industry Standards

• The company's revenue growth of 31% in Q2 2024 is a positive sign, but its gross margin loss and significant operating expenses are concerning when compared to industry benchmarks.
• The company's reliance on external financing and its going concern uncertainty are not typical for established companies in the healthcare software sector.
• The company's shift from BEAM to iRWD is a strategic move, but its success will depend on its ability to compete with other companies offering similar solutions.
• The company's internal control weaknesses are a significant concern and need to be addressed to meet industry standards for financial reporting.

Management Changes

Related Party Transactions

• The company received gross proceeds of $1.6 million in connection with shareholder loans with a related party investor.
• The company received gross proceeds of $0.4 million in connection with non-convertible shareholder loans with related party investors.
• The company issued PIPE Notes to related party investors for $1.0 million.
• The company issued Convertible Promissory Notes to related party investors for $12.3 million.
• The company assumed Data Knights liabilities, which included existing loan extensions to related parties.

Stakeholder Impact

• Shareholders face significant risk due to the company's going concern uncertainty and potential dilution from future equity offerings.
• Employees may be impacted by potential cost-cutting measures or restructuring due to the company's financial difficulties.
• Customers may experience disruptions in service or product development due to the company's financial instability.
• Suppliers and creditors face increased risk of non-payment due to the company's financial challenges.

Next Steps

• The company needs to secure additional financing to continue operations.
• The company needs to address the material weaknesses in its internal controls over financial reporting.
• The company needs to successfully execute its strategic shift from the BEAM platform to iRWD sales.
• The company needs to resolve the events of default under the Yorkville Note and SEPA.
• The company needs to file a registration statement with the SEC for the resale by Yorkville of the shares of Common Stock issued under the SEPA.

Key Dates

Keywords

medical imaging, healthcare software, real-world data, subscription revenue, web imaging, financial results, going concern, convertible debt, equity financing, internal controls, SEPA, Yorkville, PIPE Notes, warrants